会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 15. 发明公开
    • KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
    • 犬尿氨酸3单加氧酶抑制剂,药物组合物及其方法使用
    • EP3049077A2
    • 2016-08-03
    • EP14847911.6
    • 2014-09-23
    • CHDI Foundation, Inc.
    • DOMINGUEZ, CeliaTOLEDO-SHERMAN, Leticia M.PRIME, MichaelMITCHELL, WilliamWENT, Naomi
    • A61K31/381
    • C07D413/12C07D209/08C07D213/46C07D215/18C07D217/02C07D231/56C07D235/08C07D237/28C07D239/74C07D241/42C07D261/20C07D263/56C07D277/24C07D277/64C07D307/79C07D319/18C07D333/06C07D333/10C07D333/28C07D407/12
    • Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
    • 某些化合物,或其药学上可接受的盐或前药,在被提供。 所以提供了药物组合物,包含至少一种化合物,或其药学上可接受的盐或前药,在描述的和一种或多种药学上可接受的载体。 治疗某些疾病以及响应于KMO活性的抑制的疾病的患者的方法中,其包括施用来搜索患者中的至少一种化合物,或其药学上可接受的盐或前药的量,描述在有效减少体征或症状 疾病或障碍是游离缺失盘。 这些疾病包括神经变性疾病:如亨廷顿病。 如此描述是治疗方法包括施用至少一种化合物,或其药学上可接受的盐或前药,被描述在作为单一活性剂或施用至少一种化合物,或其药学上可接受的盐或前药,在组合的本文所述的一个或 多种其他治疗剂。 这样提供了用于能够KMO抑制活性的筛选化合物的方法。